CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

(2014) Tai Hato et al.   HEPATOLOGY

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma

(2014) Pengyuan Yang et al.   National Science Review

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma

(2013) Virginia Hernandez–Gea et al.   GASTROENTEROLOGY

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma

(2013) Tobias Flecken et al.   HEPATOLOGY

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice

(2013) Yunching Chen et al.   HEPATOLOGY

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Inhibition of stromal CXCR4 impairs development of lung metastases

(2012) Crescenzo D’Alterio et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hypoxia-Inducible Factors in Physiology and Medicine

(2012) Gregg L. Semenza   CELL

Impairment of CD4+cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma

(2012) Junliang Fu et al.   HEPATOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas

(2011) D Tseng et al.   BRITISH JOURNAL OF CANCER

HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF

(2011) Charlotte Rolny et al.   CANCER CELL

Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity

(2011) Yuhui Huang et al.   CANCER CELL

CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

(2011) D. G. Duda et al.   CLINICAL CANCER RESEARCH

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

HCC and angiogenesis: possible targets and future directions

(2011) Andrew X. Zhu et al.   Nature Reviews Clinical Oncology

Hepatocellular Carcinoma with Immature T-Cell (T-lymphoblastic) Proliferation

(2010) Shin Eun et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells

(2010) S. Hiratsuka et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 Oncogene

(2009) Dawang Zhou et al.   CANCER CELL

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

(2008) Rose Du et al.   CANCER CELL

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE